Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults

Tzefos, Maria; Harris, Kira B.; Brackett, Adriane

doi:10.1345/aph.1q379

Cited by 18 publications

(14 citation statements)

References 33 publications

(66 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment with GLP-1 RAs improve insulin resistance and glucose homoeostasis in patients with Type 2 DM [6,7]. The use of these agents, also have a low risk of hypoglycemia because of their mode of action.…”

Section: Introductionmentioning

confidence: 99%

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Mazidi

Karimi

Rezaie

et al. 2017

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials Article (Accepted Version) http://sro.sussex.ac.uk Mazidi, Mohsen, Karimi, Ehsan, Rezaie, Peyman and Ferns, Gordon A (2016) Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of Diabetes and its Complications. ISSN 1056-8727 This version is available from Sussex Research Online: http://sro.sussex.ac.uk/61270/ This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version. Copyright and reuse:Sussex Research Online is a digital repository of the research output of the University.Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. methods were used for quantitative data synthesis. Sensitivity analysis was conducted using the leave-one-out method. Heterogeneity was quantitatively assessed using the I 2 index. Random effects meta-regression was performed using unrestricted maximum likelihood method to evaluate the impact of potential moderator. ÔØ Å ÒÙ×Ö ÔØ A C C E P T E DInternational Prospective Register for Systematic Reviews (PROSPERO) number CRD42016036868.Results: Meta-analysis of the data from 7 treatment arms revealed a significant reduction in serum CRP concentrations following treatment with GLP-1 RAs (WMD -2.14 (mg/dL), 95% CI -3.51, -0.78, P=0.002; I 2 96.1%). Removal of one study in the meta-analysis did not change the result in the sensitivity analysis (WMD -2.14(mg/dL), 95% CI -3.51, -0.78, P=0.002; I 2 96.1%), indicating that our results could not be solel...

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Mazidi

Karimi

Rezaie

et al. 2017

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

show abstract

“…5,6 EX and LIR have already been successfully used in the treatment of patients with T2DM, 7 and the other drugs are now still in Phase II or III clinical trials.…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Sun

Chai

et al. 2015

Diabetes Technology & Therapeutics

104

View full text Add to dashboard Cite

Introduction: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new class of drugs used in the treatment of type 2 diabetes mellitus (T2DM). Gastrointestinal (GI) adverse events (AEs) are the most frequently reported treatment-related AEs for GLP-1 RAs. We aim to evaluate the effect of GLP-1 RAs on the incidence of GI AEs of T2DM. Materials and Methods: The overview of the GI events of GLP-1 RAs has been performed on relevant publications through the literature search, such as MEDLINE, EMBASE, Cochrane Library, and ClinicalTrials.gov The manufacturer was contacted regarding unpublished data. We analyzed direct and indirect comparisons of different treatments using Bayesian network meta-analysis. Results: Taspoglutide 30 mg once weekly (TAS30QW) and lixisenatide 30 lg twice daily (LIX30BID) were ranked the top two drugs in terms of GI AEs versus placebo. The odds ratios of nausea and vomiting for TAS30QW were 11.8 (95% confidence interval [CI], 2.89, 46.9) and 51.7 (95% CI, 7.07, 415), respectively, and that of diarrhea was 4.93 (95% CI, 1.75, 14.7) for LIX30BID. Conclusions: Our study found all GLP-1 RA dose regimens significantly increased the incidence of GI AEs, compared with placebo or conventional treatment. The occurrence of GI AEs was different with diverse dose regimens of GLP-1 RAs. TAS30QW had the maximum probability to occur nausea and vomiting, whereas LIX30BID had the maximum probability to cause development of diarrhea versus other treatments.

show abstract

“…Other GLP-1 RAs currently under development for the treatment of T2DM include once daily lixisenatide [44], and once weekly albiglutide [45] and semaglutide [46]. Patients utilizing GLP-1 RAs as part of their T2DM therapy have reported improved quality of life and satisfaction with treatment, particularly for the once daily and once weekly preparations [45,[47][48][49].…”

Section: Glp-1 Receptor Agonistsmentioning

confidence: 99%

“…Patients utilizing GLP-1 RAs as part of their T2DM therapy have reported improved quality of life and satisfaction with treatment, particularly for the once daily and once weekly preparations [45,[47][48][49].…”

Section: Glp-1 Receptor Agonistsmentioning

confidence: 99%

Impact of Newer Medications for Type 2 Diabetes on Body Weight

Pedersen¹

2013

Curr Obes Rep

View full text Add to dashboard Cite

Most patients with type 2 diabetes (T2DM) struggle with excess body weight. Many management strategies for achievement of euglycemia in T2DM are associated with weight gain, which worsens insulin resistance over time, increases health risk associated with obesity, and is associated with poor compliance with treatment. This review will discuss a host of new medications for management of hyperglycemia that have emerged and are emerging which are weight neutral, or facilitate weight loss. Incretin therapies are reviewed, including DPP-4 inhibitors which are weight neutral, and GLP-1 receptor agonists which can facilitate weight loss. SGLT-2 inhibitors, anticipated to become available soon, facilitate modest weight loss. Pramlintide can improve glycemic control and facilitate weight loss in T2DM patients on concomitant insulin therapy. The bile acid sequestering agent colesevelam, more recently approved for management of T2DM, modestly improves glycemic control and is weight neutral. The advent of these newer therapies makes it increasingly possible to optimize concomitant management of type 2 diabetes and obesity.

show abstract

Clinical Efficacy and Safety of Once-Weekly Glucagon-Like Peptide-1 Agonists in Development for Treatment of Type 2 Diabetes Mellitus in Adults

Abstract: Once-weekly GLP-1 agonists provide similar glycemic control with weight reduction, as well as overall higher treatment satisfaction for patients because of their ease of use and need for less-frequent dosing compared to some available agents.

Cited by 18 publications

References 33 publications

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials

Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Impact of Newer Medications for Type 2 Diabetes on Body Weight

Contact Info

Product

Resources

About